PF-07901801
Showing 26 - 50 of 1,083
Healthy Participants Trial in Brussels (PF-07258669, Placebo, Midazolam)
Recruiting
- Healthy Participants
- PF-07258669
- +2 more
-
Brussels, Bruxelles-capitale, Région DE, BelgiumBrussels Clinical Research Unit
Nov 28, 2022
Complicated Intra-abdominal Infection Trial in Japan (PF-06947386, Metronidazole)
Completed
- Complicated Intra-abdominal Infection
-
Nagoya, Aichi, Japan
- +26 more
Nov 21, 2022
Progressive Pulmonary Fibrosis, Interstitial Lung Disease Trial (Placebo, Inhaled Treprostinil, Treprostinil Ultrasonic
Not yet recruiting
- Progressive Pulmonary Fibrosis
- Interstitial Lung Disease
- Placebo
- +2 more
- (no location specified)
Jul 5, 2023
Interstitial Lung Diseases Trial in Wenzhou (Anlotinib, Placebo)
Recruiting
- Interstitial Lung Diseases
- Anlotinib
- Placebo
-
Wenzhou, Zhejiang, ChinaThe First Affiliated Hospital of Wenzhou Medical University
Apr 13, 2023
Plasmodium Falciparum Infection, Malaria Trial in Faladje, Kalifabougou, Torodo (L9LS (VRC-MALMAB0114-00-AB), Normal Saline)
Not yet recruiting
- Plasmodium Falciparum Infection
- Malaria
- L9LS (VRC-MALMAB0114-00-AB)
- Normal Saline
-
Faladje, Région De Koulikoro, Mali
- +2 more
Apr 17, 2023
Hepatic Impairment, Healthy Volunteers Trial in Orlando, Tampa (PF-07081532)
Not yet recruiting
- Hepatic Impairment
- Healthy Volunteers
-
Orlando, Florida
- +1 more
Jul 26, 2022
Atopic Dermatitis, Plaque Psoriasis Trial (PF-07038124 ointment 0.01%, Vehicle ointment, PF-07038124 ointment 0.03%)
Recruiting
- Atopic Dermatitis
- Plaque Psoriasis
- PF-07038124 ointment 0.01%
- +3 more
-
Encinitas, California
- +31 more
Jan 23, 2023
Malaria Trial in Addis Ababa (NxTekTM Malaria Pf Plus Rapid Diagnostic Test Device)
Recruiting
- Malaria
- NxTekTM Malaria Pf Plus Rapid Diagnostic Test Device
-
Addis Ababa, EthiopiaMedical Parasitology Research Unit, Aklilu Lemma Institute of Pa
Jun 29, 2022
Pleural Effusion, Heart Failure, Malignant Tumor Trial
Not yet recruiting
- Pleural Effusion
- +7 more
- (no location specified)
Mar 31, 2023
Presbyopia Trial in Memphis (BRIMOCHOL™ PF, Carbachol PF, Brimonidine tartrate)
Recruiting
- Presbyopia
- BRIMOCHOL™ PF
- +2 more
-
Memphis, TennesseeTotal Eye Care, PA
Apr 25, 2022
Naturally Acquired Malaria Immunity in Mali
Completed
- Malaria
-
Bamako, MaliUniversity of Bamako, Faculty of Medicine, Pharmacy and Odontost
Mar 29, 2022
Return of Motor and Sensory Blockade, Anesthesia, Spinal, Decrease Discharge Time Status Post Hemmoriodectomy Trial in Bronx (1%
Recruiting
- Return of Motor and Sensory Blockade
- +2 more
- 1% chloroprocaine
- 0.75% bupivacaine
-
Bronx, New YorkMontefiore Medical Center
Jan 5, 2023
Bioavailability Trial in New Haven (PF-07321332/ritonavir)
Completed
- Bioavailability
-
New Haven, ConnecticutNew Haven Clinical Research Unit
Jun 28, 2022
Pulmonary Fibrosis, Interstitial Lung Disease, Lung Fibrosis Trial in Chicago
Recruiting
- Pulmonary Fibrosis
- +3 more
-
Chicago, IllinoisPulmonary Fibrosis Foundation
Oct 28, 2022
Turkish Version of Patellofemoral Pain and Osteoarthritis
Completed
- Patellofemoral Pain Syndrome
- +2 more
-
Ankara, TurkeyGazi University
Sep 29, 2023
Healthy Trial in New Haven (PF-07295324, PF-07259955)
Active, not recruiting
- Healthy
-
New Haven, ConnecticutNew Haven Clinical Research Unit
Aug 3, 2022
Healthy Trial in Shinjuku-ku (PF-06823859, Placebo)
Completed
- Healthy
- PF-06823859
- Placebo
-
Shinjuku-ku, Tokyo, JapanMedical Corporation Shinanokai Shinanozaka Clinic
May 23, 2022
Physical Function, Multiple Chronic Conditions Trial in Chicago (Keep it Movin', Go 4 Life Self Guided Education)
Not yet recruiting
- Physical Function
- Multiple Chronic Conditions
- Keep it Movin'
- Go 4 Life Self Guided Education
-
Chicago, IllinoisRush University Medical Center
Apr 20, 2022
Obesity Trial in Anaheim (PF-07081532, Semaglutide)
Recruiting
- Obesity
-
Anaheim, CaliforniaAnaheim Clinical Trials, LLC
Jan 27, 2023
Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer, Recurrent Renal Cell Carcinoma Trial in United States
Active, not recruiting
- Clear Cell Renal Cell Carcinoma
- +3 more
- Anti-OX40 Antibody PF-04518600
- +3 more
-
Los Angeles, California
- +9 more
Aug 5, 2022